history of glp-1 drugs The transformative breakthroughs in research recognized by the 2024 Lasker~DeBakey award | Current Medicine History of glucagon-like peptide-1 receptor
Description
Diabetes (2014) 63:334658

GLP-1s: Medicaids Expenditures As of 2023, 39 state Medicaid programs had unrestricted coverage for at least one GLP-1 drug to treat T2D

Amino acid constituents of peptide I-M-150845

Risk of Hypoglycemia with Concomitant Use of Anti-Diabetic Therapy: When Saxenda is used with an insulin secretagogue (e.g., a sulfonylurea) serious hypoglycemia can occur

The second is that Canadas formulary, at least in Ontario and Nova Scotia, is restrictive, meaning that as a general principle, Canada is willing to trade options for savings

In fact, as well detail in a later section, liraglutide in 2016 became the first GLP-1 agonist shown to reduce cardiovascular events in a dedicated outcomes trial (LEADER) an immensely important finding that added another dimension to its therapeutic profile
